Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.23, RTT News reports. The firm had revenue of $14.97 million during the quarter. During the same period last year, the firm posted ($0.37) EPS.
Barinthus Biotherapeutics Price Performance
Shares of BRNS stock traded up $0.01 on Thursday, hitting $1.49. The stock had a trading volume of 7,485 shares, compared to its average volume of 23,586. The firm has a market capitalization of $58.61 million, a P/E ratio of -0.89 and a beta of -0.59. Barinthus Biotherapeutics has a 1 year low of $1.11 and a 1 year high of $4.39. The company’s 50 day moving average price is $1.29 and its 200-day moving average price is $1.58.
Analysts Set New Price Targets
Several research analysts recently weighed in on the company. Alliance Global Partners reduced their price target on Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Barinthus Biotherapeutics in a report on Thursday, September 26th.
About Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
See Also
- Five stocks we like better than Barinthus Biotherapeutics
- What to Know About Investing in Penny Stocks
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- Buy P&G Now, Before It Sets A New All-Time High
- Breakout Alert: Qualcomm Just Hit The Rally Button
- P/E Ratio Calculation: How to Assess Stocks
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
